Theracryf PLC Result of AGM
18 Luglio 2024 - 4:02PM
RNS Regulatory News
RNS Number : 9906W
Theracryf PLC
18 July 2024
TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Result of AGM and Investor
Presentation
Alderley Park, UK - 18 July 2024: TheraCryf plc
(AIM: TCF), the clinical stage drug development company focussing
on oncology and neuropsychiatry, held its AGM today and all
resolutions were passed. The AGM voting results are available
on the Company's website Here.
-Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie
Toyne-Sewell / Jack Kincade
|
+44 207 457 2020
theracryf@Instinctif.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan indications]. Its
strategy is to generate compelling data sets to preclinical and/or
clinical proof of concept and partner its clinical programmes with
mid‐size to large pharma for larger trials and commercialisation.
As well as a number of industry partnerships with companies,
including Stalicla SA, in neurodevelopmental disorders. The Company
has sourced know how for programmes from companies such as Shire
(now Takeda).
TheraCryf has worked with and has ongoing
collaborations with major universities and hospitals such as the
University of Manchester, La Sapienza (Università di Roma), the
Erasmus Medical Centre, Rotterdam, Kings College London and
University of Connecticut.
The Company has its headquarters and registered
office at Alderley Park, Cheshire. It is listed on AIM in London
and trades under the ticker symbol TCF.
For further information, please visit:
www.theracryf.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGBXGDRCUBDGSI
Grafico Azioni Theracryf (LSE:TCF)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Theracryf (LSE:TCF)
Storico
Da Dic 2023 a Dic 2024
